Author

Fariba Khandan

Observed names: F Khandan, F. Khandan

Institutions: Centre Léon Bérard, Agaplesion Markus Hospital

OpenAlex ID: A5035305874

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

2014 · Gunter von Minckwitz, Andreas Schneeweiss, et al. · The Lancet Oncology · 1,033

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

2010 · Jens Huober, Gunter von Minckwitz, et al. · Breast Cancer Research and Treatment · 291

PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

2014 · Sibylle Loibl, Gunter von Minckwitz, et al. · Journal of Clinical Oncology · 260

PDF

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

2014 · G. von Minckwitz, S. Loibl, et al. · Annals of Oncology · 138

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

2019 · T. Bachelot, E. Ciruelos, et al. · Annals of Oncology · 119

PDF

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

2021 · D. Miles, E. Ciruelos, et al. · Annals of Oncology · 102

PDF

Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

2011 · Gunter von Minckwitz, Berit Maria Müller, et al. · Journal of Clinical Oncology · 87

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)

2013 · Jens Huober, Peter A. Fasching, et al. · European Journal of Cancer · 80

Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

2016 · G von Minckwitz, S Loibl, et al. · Cancer Research · 63

A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto).

2013 · Gunter Von Minckwitz, Andreas Schneeweiss, et al. · Journal of Clinical Oncology · 56

Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer

2012 · Antonia Sophie Wenners, Keyur Mehta, et al. · PLoS ONE · 51

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

2012 · I Witzel, S Loibl, et al. · British Journal of Cancer · 33

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

2012 · S Darb-Esfahani, R Kronenwett, et al. · British Journal of Cancer · 24

PDF

Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto)

2017 · M. Untch, A. Schneeweiss, et al. · Annals of Oncology · 21

Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies

2013 · S Loibl, C Denkert, et al. · Cancer Research · 13

S3-6: Neoadjuvant Chemotherapy of Paclitaxel with or without Rad001: Results of the Non-Responder Part of the GEPARQUINTO Study (GBG 44).

2011 · J Huober, C Hanusch, et al. · Cancer Research · 7

p53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – A translational subproject of the GeparSixto trial

2015 · S. Darb-Esfahani, W. Weichert, et al. · Annals of Oncology · 1

Abstract P5-12-01: Elderly Patients in a Prospective Observation Study on Trastuzumab (Herceptin®) in the Adjuvant Treatment of Breast Cancer

2010 · P Dall, F Siedentopf, et al. · Cancer Research · 1

Magseed®-guided long-term marking of target lymph nodes in neoadjuvant therapy of early breast cancer patients - experiences in 13 patients

2021 · T Schnitzbauer, F Khandan, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie

Magseed®-guided long-term marking of target lymph nodes in neoadjuvant therapy of early breast cancer patients – first experiences and prospectives

2020 · M Thill, F Khandan, et al. · Geburtshilfe und Frauenheilkunde

Effektivität und Nebenwirkungen des DigniCap® Systems zur Vermeidung von Zytostatika induzierter Alopezie

2018 · L Traub, C Brandi, et al. · Geburtshilfe und Frauenheilkunde

Abstract P6-11-07: Effectiveness and adverse events of DigniCap® scalp cooling system

2018 · L Traub, C Brandi, et al. · Cancer Research

Effektivität und Nebenwirkungen des DigniCap® Systems zur Vermeidung von Zytostatika induzierter Alopezie

2017 · L Traub, C Brandi, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie

Effektivität und Nebenwirkungen des DigniCap® Systems zur Vermeidung von Zytostatika induzierter Alopezie

2016 · L Traub, J Barinoff, et al. · Geburtshilfe und Frauenheilkunde

Abstract P2-08-15: Impact of OncotypeDX on treatment decision for early stage, hormone-receptor-positive breast cancer

2016 · L Anastasiadou, M Schneider, et al. · Cancer Research

Works count: 29

Citation count: 2,380

H-index: 14

I10-index: 15